RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT GRADE 3A FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GRADE 3A FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT GRADE 3A FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for patients with relapsed lymphoma
Disease control OngoingThis study tests whether combining two immunotherapy drugs (rituximab and pembrolizumab) with or without a chemotherapy drug (lenalidomide) can shrink tumors in people whose follicular lymphoma or diffuse large B-cell lymphoma has returned after previous treatment. About 53 adult…
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Experimental drug targets Hard-to-Treat lymphoma
Disease control OngoingThis early-stage trial tests a new drug called MEDI-570 in people with certain types of T-cell lymphoma that have come back or not responded to treatment. The main goals are to find the best dose and check for side effects. The drug works by helping the immune system attack cance…
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Two-Drug combo shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and vorinostat (a drug that blocks enzymes cancer cells need to grow)—in 52 adults with certain types of lymphoma that had returned or stopped resp…
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC